CENTRALISED PROCEDURE PROCESS

The centralised procedure (CP) is the European Union-wide procedure for the authorisation of medicines, where there is a single marketing- authorisation application to EMA, a single evaluation and a single authorisation.  Only certain medicines are eligible for the centralised procedure. 

The centralised procedure (CP) is the European Union-wide procedure for the authorisation of medicines, where there is a single marketing- authorisation application to EMA, a single evaluation and a single authorisation.  Only certain medicines are eligible for the centralised procedure. 
May 28, 2021

The centralised procedure (CP) is the European Union-wide procedure for the authorisation of medicines, where there is a single marketing authorisation application to EMA, a single evaluation and a single authorisation.  Only certain medicines are eligible for the centralised procedure.

This procedure allows the marketing authorisation holder to market the medicine and make it available to patients and healthcare professionals throughout the EU on the basis of a single marketing authorisation.

The centralised procedure is compulsory for:

 

  • Medicines derived from biotechnology processes, such as genetic engineering
  • Advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines
  • Orphan medicines (medicines for rare diseases)
  • Veterinary medicines for use as growth or yield enhancers

Today, the great majority of new, innovative medicines (including COVID-19 vaccines) pass through the centralised authorisation procedure in order to be marketed in the EU.

However, under EU law, EMA has no authority to actually permit marketing in the different EU countries. The

Once granted by the European Commission, the centralised marketing authorisation is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.

Commission decisions are published in the Community Register of medicinal products for human use.

The benefits of the centralised procedure for EU citizens are:

  • Medicines are authorized in all EU countries at the same time
  • Centralised safety monitoring
  • Product Information available in all EU languages at the same time

The process of a CP is quite challenging and there are a lot of timelines to be kept, including local activities needed prior to commercialization.

We have summarized all CP steps in this flow chart for you to download and keep always at hand.

 

DOWNLOAD HERE

 

Furthermore, you can send us an email: info@asphalion.com

We will be more than happy to assist you!

Search News & Events

  • Filter by category

Share

Related news and events

RBDCOV | 14-months follow-up meeting

The second face-to-face RBDCOV meeting is taking place today at Palau Macaya in Barcelona! Our expert, Chris Mann, is attending the meeting in person. After

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting